<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907478</url>
  </required_header>
  <id_info>
    <org_study_id>20080009</org_study_id>
    <nct_id>NCT00907478</nct_id>
  </id_info>
  <brief_title>Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)</brief_title>
  <official_title>A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate changes in bone marrow morphology (structure) after
      long-term exposure to romiplostim.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants diagnosed with ITP according to the American Society of Hematology (ASH)
      Guidelines were sequentially enrolled into the following groups:

        -  Bone marrow biopsy at Baseline and Year 1

        -  Bone marrow biopsy at Baseline and Year 2

        -  Bone marrow biopsy at Baseline and Year 3.

      All participants received romiplostim for 3 years, unless withdrawn from the study early.
      Participants returned for one visit for End of Study (EOS) procedures 4 weeks after
      romiplostim discontinuation, or, for participants who were withdrawn from the study due to
      the presence of collagen fibrosis, or had a change to grade 3 reticulin, at 12 weeks after
      discontinuation of romiplostim.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Collagen Fibrosis</measure>
    <time_frame>At Years 1, 2 or 3 after initial exposure of romiplostim</time_frame>
    <description>The percentage of participants who developed collagen fibrosis as evidenced by trichrome staining. Bone marrow biopsy samples were assessed using the modified Bauermeister grading scale by a central laboratory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Collagen Fibrosis 12 Weeks After Romiplostim Discontinuation in Participants Who Developed Collagen Fibrosis at Years 1, 2, or 3</measure>
    <time_frame>12 weeks after romiplostim discontinuation</time_frame>
    <description>The number of participants with collagen fibrosis as evidenced by trichrome staining 12 weeks after romiplostim discontinuation in participants who developed collagen fibrosis at Years 1, 2, or 3 after initial exposure of romiplostim, assessed by the central laboratory using the modified Bauermeister grading scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Developed an Increased Modified Bauermeister Grade</measure>
    <time_frame>At Year 1, Year 2, or Year 3 post romiplostim exposure</time_frame>
    <description>Increased modified Bauermeister grade refers to an increase by ≥ 2 severity grades or an increase to grade 4 (ie, grade 0 to 2-4, grade 1 to 3-4, grade 2 to 4, or grade 3 to 4 over baseline). The modified Bauermeister scale provides a means of assessing the development of increased reticulin and collagen in bone marrow according to the following: Grade 0: No reticulin fibers demonstrable; Grade 1: Occasional fine individual fibers and foci of a fine fiber network; Grade 2: Fine fiber network throughout most of the section; no coarse fibers; Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining); Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Relevant Changes in Total Cardiac Output Corrected (QTc) Intervals</measure>
    <time_frame>Baseline, Week 3 and Week 12</time_frame>
    <description>A clinically relevant change in QTc (Fridericia) interval is defined as an absolute QTc interval &gt;500 ms or a QTc Interval increase from Baseline &gt;60 ms post romiplostim exposure. 12-lead electrocardiograms (ECG) were performed in triplicate at Baseline, Week 3 and Week 12; the average of of the 3 values at each assessment was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement of Reticulin to a Grade of ≤ 2 for Participants Who Developed Grade 3 Reticulin</measure>
    <time_frame>12 weeks after romiplostim discontinuation</time_frame>
    <description>The number of participants who had any improvement of reticulin to a grade of ≤ 2 for participants who developed grade 3 reticulin after initial exposure to romiplostim as measured by the modified Bauermeister grading scale. The modified Bauermeister scale provides a means of assessing the development of increased reticulin and collagen in bone marrow according to the following: Grade 0: No reticulin fibers demonstrable; Grade 1: Occasional fine individual fibers and foci of a fine fiber network; Grade 2: Fine fiber network throughout most of the section; no coarse fibers; Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining); Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CTCAE Grade ≥ 2 Shift in Anemia or Neutropenia</measure>
    <time_frame>From the first dose of study drug until 4 weeks after treatment discontinuation or 12 weeks after treatment discontinuation for patients who developed collagen fibrosis or a change to grade 3 reticulin; the overall median treatment duration was 154 weeks.</time_frame>
    <description>Anemia was identified by laboratory values with hemoglobin &lt; the lower limit of normal (LLN) or the Medical Dictionary for Regulatory Activities (MedDRA) terms prespecified by the sponsor. Neutropenia was identified by laboratory values with absolute neutrophil count &lt;1.8x10^9/L or the MedDRA terms pre-specified by the sponsor. Severity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, based on the following: Grade 1: Mild AE; Grade 2: Moderate AE; Grade 3: Severe AE; Grade 4: Life-threatening or disabling AE; Grade 5: Death related to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From the first dose of study drug until 4 weeks after treatment discontinuation or 12 weeks after treatment discontinuation for patients who developed collagen fibrosis or a change to grade 3 reticulin; the overall median treatment duration was 154 weeks.</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant that did not necessarily have a causal relationship with this treatment, or any such occurrence or worsening of a pre-existing medical condition from the first dose of investigational product through the last study visit. A serious adverse event is defined as an AE that is fatal or life threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other significant medical hazard. The relationship of each AE to the study drug was assessed by the investigator. The severity of each AE was graded using using CTCAE 3.0; For any AEs not listed in CTCAE, the Amgen Standard Severity Scoring System was used: 1: Mild- Aware of sign or symptom, but easily tolerated; 2 Moderate- Discomfort enough to cause interference with usual activity; 3: Severe- Incapacitating with inability to work or do usual activity; 4: Life-threatening; 5: Fatal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Antibodies or Neutralizing Antibodies to Romiplostim or to Endogenous Thrombopoietin</measure>
    <time_frame>Every 24 weeks and at the end of study visit (4 weeks or 12 weeks after study drug discontinuation).</time_frame>
    <description>Two validated assays were used to test for antibodies to romiplostim, the thrombopoietin-mimetic peptide component of romiplostim (TMP) and to endogenous thrombopoietin (TPO). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies.
Persistent antibodies were those positive at the last timepoint tested and transient are defined as positive post-dose but negative at the last time point tested.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Thrombocytopenia</condition>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>Romiplostim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years.
The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>romiplostim</intervention_name>
    <description>Romiplostim administered by subcutaneous injection</description>
    <arm_group_label>Romiplostim</arm_group_label>
    <other_name>Nplate®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ITP according to American Society of Hematology (ASH) guidelines

          -  Subject must have had a bone marrow biopsy within one year prior to planned first dose
             of romiplostim (with available bone marrow tissue block or unstained histological
             slides to send to a central laboratory for interpretation) or must consent to a
             pre-treatment bone marrow biopsy within 3 weeks prior to planned first dose of
             romiplostim. Central laboratory interpretation is required prior to first dose of
             romiplostim

          -  Subject must agree to a scheduled bone marrow biopsy at Year 1, Year 2, or Year 3
             following romiplostim treatment and any unscheduled biopsies if clinically indicated

          -  Subject ≥18 years of age

          -  Baseline bone marrow reticulin grade of 0, 1, 2, or 3 according to the modified
             Bauermeister grading scheme as assessed by central laboratory interpretation

          -  Platelet count &lt; 50 x 10^9/L

          -  Must have received at least 1 prior ITP therapy (examples of ITP therapy include
             corticosteroids, intravenous immunoglobulin [IVIG], splenectomy)

          -  Subject (or legally-acceptable representative) is willing and able to provide written
             informed consent

        Exclusion Criteria:

          -  Baseline bone marrow biopsy positive for collagen fibrosis

          -  Any known history of or currently active bone marrow stem cell disorder, hematological
             malignancy, myeloproliferative disorder, myelodysplastic syndrome

          -  Any current active malignancy

          -  Any prior exposure to cytostatic chemotherapy or radiotherapy for malignancy

          -  Subject has undergone pacemaker placement, cardiac ablation of arrhythmia, and/or any
             current treatment with Vaughan Williams Class IA - IC and Class III agents (Vaughan
             Williams, 1970)

          -  Subject has participated in any study evaluating pegylated recombinant human
             megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human
             thrombopoietin (rHuTPO), or thrombopoietin receptor agonists (ie romiplostim or
             eltrombopag)

          -  Subject has a known hypersensitivity to any recombinant E coli-derived product

          -  Subject is currently enrolled in or has not yet completed (at least 4 weeks since
             ending) other investigational device or drug trial(s) or subject is receiving other
             investigational agent(s)

          -  Other investigational procedures are excluded

          -  Subject of child-bearing potential is evidently pregnant (eg positive pregnancy test)
             or is breast feeding

          -  Subject is not using adequate contraceptive precautions

          -  Subject has any kind of disorder that compromises the ability of the subject to give
             written informed consent and does not have a legally acceptable representative and/or
             is unable to comply with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Janssens A, Rodeghiero F, Anderson D, Chong BH, Boda Z, Pabinger I, Červinek L, Terrell DR, Wang X, Franklin J. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol. 2016 Jun;95(7):1077-87. doi: 10.1007/s00277-016-2682-2. Epub 2016 Apr 30.</citation>
    <PMID>27130310</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <results_first_submitted>December 19, 2014</results_first_submitted>
  <results_first_submitted_qc>December 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2015</results_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Thrombocytopenic Purpura</keyword>
  <keyword>Idiopathic Thrombocytopenia Purpura</keyword>
  <keyword>Immune Thrombocytopenic Purpura</keyword>
  <keyword>Immune Thrombocytopenia</keyword>
  <keyword>ITP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible patients were adults diagnosed with immune (idiopathic) thrombocytopenic purpura (ITP) with a platelet count &lt; 50 x 10^9/L. The first patient enrolled 11 August 2009 and the last patient was enrolled 11 November 2010. Participants were enrolled at 60 study centers in Australia, Europe, and North America.</recruitment_details>
      <pre_assignment_details>204 patients were screened, 35 were considered screen failures. Participants were enrolled sequentially into the following cohorts: • Bone marrow biopsy at Baseline and Year 1 • Bone marrow biopsy at Baseline and Year 2 • Bone marrow biopsy at Baseline and Year 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 2.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23">Defined as participants who completed the full 3 years and completed the end of study visit.</participants>
                <participants group_id="P2" count="33">Defined as participants who completed the full 3 years and completed the end of study visit.</participants>
                <participants group_id="P3" count="47">Defined as participants who completed the full 3 years and completed the end of study visit.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requirement for alternative therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 1.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 2.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 3.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" spread="17.1"/>
                    <measurement group_id="B2" value="48.6" spread="16.5"/>
                    <measurement group_id="B3" value="46.6" spread="16.3"/>
                    <measurement group_id="B4" value="49.8" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since ITP Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.94" spread="10.29"/>
                    <measurement group_id="B2" value="10.50" spread="11.87"/>
                    <measurement group_id="B3" value="5.36" spread="6.41"/>
                    <measurement group_id="B4" value="8.24" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Prior ITP Therapies</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Had Splenectomy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any Prior History of Bone Marrow Abnormalities</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Collagen Fibrosis</title>
        <description>The percentage of participants who developed collagen fibrosis as evidenced by trichrome staining. Bone marrow biopsy samples were assessed using the modified Bauermeister grading scale by a central laboratory.</description>
        <time_frame>At Years 1, 2 or 3 after initial exposure of romiplostim</time_frame>
        <population>Participants who had evaluable trichrome stain results</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Collagen Fibrosis</title>
          <description>The percentage of participants who developed collagen fibrosis as evidenced by trichrome staining. Bone marrow biopsy samples were assessed using the modified Bauermeister grading scale by a central laboratory.</description>
          <population>Participants who had evaluable trichrome stain results</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="3.4" lower_limit="0.4" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Collagen Fibrosis 12 Weeks After Romiplostim Discontinuation in Participants Who Developed Collagen Fibrosis at Years 1, 2, or 3</title>
        <description>The number of participants with collagen fibrosis as evidenced by trichrome staining 12 weeks after romiplostim discontinuation in participants who developed collagen fibrosis at Years 1, 2, or 3 after initial exposure of romiplostim, assessed by the central laboratory using the modified Bauermeister grading scale.</description>
        <time_frame>12 weeks after romiplostim discontinuation</time_frame>
        <population>Participants with collagen fibrosis at Year 1, 2 or 3 and with available trichome staining results 12 weeks after study drug discontinuation. One participant with collagen fibrosis refused the follow-up bone marrow biopsy.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Collagen Fibrosis 12 Weeks After Romiplostim Discontinuation in Participants Who Developed Collagen Fibrosis at Years 1, 2, or 3</title>
          <description>The number of participants with collagen fibrosis as evidenced by trichrome staining 12 weeks after romiplostim discontinuation in participants who developed collagen fibrosis at Years 1, 2, or 3 after initial exposure of romiplostim, assessed by the central laboratory using the modified Bauermeister grading scale.</description>
          <population>Participants with collagen fibrosis at Year 1, 2 or 3 and with available trichome staining results 12 weeks after study drug discontinuation. One participant with collagen fibrosis refused the follow-up bone marrow biopsy.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Developed an Increased Modified Bauermeister Grade</title>
        <description>Increased modified Bauermeister grade refers to an increase by ≥ 2 severity grades or an increase to grade 4 (ie, grade 0 to 2-4, grade 1 to 3-4, grade 2 to 4, or grade 3 to 4 over baseline). The modified Bauermeister scale provides a means of assessing the development of increased reticulin and collagen in bone marrow according to the following: Grade 0: No reticulin fibers demonstrable; Grade 1: Occasional fine individual fibers and foci of a fine fiber network; Grade 2: Fine fiber network throughout most of the section; no coarse fibers; Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining); Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining).</description>
        <time_frame>At Year 1, Year 2, or Year 3 post romiplostim exposure</time_frame>
        <population>Participants who had evaluable reticulin silver stain results</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Developed an Increased Modified Bauermeister Grade</title>
          <description>Increased modified Bauermeister grade refers to an increase by ≥ 2 severity grades or an increase to grade 4 (ie, grade 0 to 2-4, grade 1 to 3-4, grade 2 to 4, or grade 3 to 4 over baseline). The modified Bauermeister scale provides a means of assessing the development of increased reticulin and collagen in bone marrow according to the following: Grade 0: No reticulin fibers demonstrable; Grade 1: Occasional fine individual fibers and foci of a fine fiber network; Grade 2: Fine fiber network throughout most of the section; no coarse fibers; Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining); Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining).</description>
          <population>Participants who had evaluable reticulin silver stain results</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="10.3"/>
                    <measurement group_id="O2" value="5.1" lower_limit="0.6" upper_limit="17.3"/>
                    <measurement group_id="O3" value="12.1" lower_limit="5.0" upper_limit="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinically Relevant Changes in Total Cardiac Output Corrected (QTc) Intervals</title>
        <description>A clinically relevant change in QTc (Fridericia) interval is defined as an absolute QTc interval &gt;500 ms or a QTc Interval increase from Baseline &gt;60 ms post romiplostim exposure. 12-lead electrocardiograms (ECG) were performed in triplicate at Baseline, Week 3 and Week 12; the average of of the 3 values at each assessment was used.</description>
        <time_frame>Baseline, Week 3 and Week 12</time_frame>
        <population>All participants who received at least one dose of romiplostim.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinically Relevant Changes in Total Cardiac Output Corrected (QTc) Intervals</title>
          <description>A clinically relevant change in QTc (Fridericia) interval is defined as an absolute QTc interval &gt;500 ms or a QTc Interval increase from Baseline &gt;60 ms post romiplostim exposure. 12-lead electrocardiograms (ECG) were performed in triplicate at Baseline, Week 3 and Week 12; the average of of the 3 values at each assessment was used.</description>
          <population>All participants who received at least one dose of romiplostim.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement of Reticulin to a Grade of ≤ 2 for Participants Who Developed Grade 3 Reticulin</title>
        <description>The number of participants who had any improvement of reticulin to a grade of ≤ 2 for participants who developed grade 3 reticulin after initial exposure to romiplostim as measured by the modified Bauermeister grading scale. The modified Bauermeister scale provides a means of assessing the development of increased reticulin and collagen in bone marrow according to the following: Grade 0: No reticulin fibers demonstrable; Grade 1: Occasional fine individual fibers and foci of a fine fiber network; Grade 2: Fine fiber network throughout most of the section; no coarse fibers; Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining); Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining).</description>
        <time_frame>12 weeks after romiplostim discontinuation</time_frame>
        <population>Participants with Grade 3 reticulin at Year 1, 2 or 3 and who had a follow-up bone marrow biopsy 12 weeks after romiplostim discontinuation. Two participants with grade 3 reticulin did not have a bone marrow biopsy performed 12 weeks after romiploastim discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement of Reticulin to a Grade of ≤ 2 for Participants Who Developed Grade 3 Reticulin</title>
          <description>The number of participants who had any improvement of reticulin to a grade of ≤ 2 for participants who developed grade 3 reticulin after initial exposure to romiplostim as measured by the modified Bauermeister grading scale. The modified Bauermeister scale provides a means of assessing the development of increased reticulin and collagen in bone marrow according to the following: Grade 0: No reticulin fibers demonstrable; Grade 1: Occasional fine individual fibers and foci of a fine fiber network; Grade 2: Fine fiber network throughout most of the section; no coarse fibers; Grade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining); Grade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining).</description>
          <population>Participants with Grade 3 reticulin at Year 1, 2 or 3 and who had a follow-up bone marrow biopsy 12 weeks after romiplostim discontinuation. Two participants with grade 3 reticulin did not have a bone marrow biopsy performed 12 weeks after romiploastim discontinuation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CTCAE Grade ≥ 2 Shift in Anemia or Neutropenia</title>
        <description>Anemia was identified by laboratory values with hemoglobin &lt; the lower limit of normal (LLN) or the Medical Dictionary for Regulatory Activities (MedDRA) terms prespecified by the sponsor. Neutropenia was identified by laboratory values with absolute neutrophil count &lt;1.8x10^9/L or the MedDRA terms pre-specified by the sponsor. Severity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, based on the following: Grade 1: Mild AE; Grade 2: Moderate AE; Grade 3: Severe AE; Grade 4: Life-threatening or disabling AE; Grade 5: Death related to AE.</description>
        <time_frame>From the first dose of study drug until 4 weeks after treatment discontinuation or 12 weeks after treatment discontinuation for patients who developed collagen fibrosis or a change to grade 3 reticulin; the overall median treatment duration was 154 weeks.</time_frame>
        <population>All participants who received at least one dose of romiplostim</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CTCAE Grade ≥ 2 Shift in Anemia or Neutropenia</title>
          <description>Anemia was identified by laboratory values with hemoglobin &lt; the lower limit of normal (LLN) or the Medical Dictionary for Regulatory Activities (MedDRA) terms prespecified by the sponsor. Neutropenia was identified by laboratory values with absolute neutrophil count &lt;1.8x10^9/L or the MedDRA terms pre-specified by the sponsor. Severity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, based on the following: Grade 1: Mild AE; Grade 2: Moderate AE; Grade 3: Severe AE; Grade 4: Life-threatening or disabling AE; Grade 5: Death related to AE.</description>
          <population>All participants who received at least one dose of romiplostim</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTCAE grade ≥2 shift in anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="1.3" upper_limit="16.5"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0.5" upper_limit="13.7"/>
                    <measurement group_id="O3" value="8.7" lower_limit="3.3" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTCAE grade ≥2 shift in neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="2.2" upper_limit="19.2"/>
                    <measurement group_id="O2" value="6.0" lower_limit="1.3" upper_limit="16.5"/>
                    <measurement group_id="O3" value="13.0" lower_limit="6.1" upper_limit="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant that did not necessarily have a causal relationship with this treatment, or any such occurrence or worsening of a pre-existing medical condition from the first dose of investigational product through the last study visit. A serious adverse event is defined as an AE that is fatal or life threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other significant medical hazard. The relationship of each AE to the study drug was assessed by the investigator. The severity of each AE was graded using using CTCAE 3.0; For any AEs not listed in CTCAE, the Amgen Standard Severity Scoring System was used: 1: Mild- Aware of sign or symptom, but easily tolerated; 2 Moderate- Discomfort enough to cause interference with usual activity; 3: Severe- Incapacitating with inability to work or do usual activity; 4: Life-threatening; 5: Fatal.</description>
        <time_frame>From the first dose of study drug until 4 weeks after treatment discontinuation or 12 weeks after treatment discontinuation for patients who developed collagen fibrosis or a change to grade 3 reticulin; the overall median treatment duration was 154 weeks.</time_frame>
        <population>All participants who received at least one dose of romiplostim</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant that did not necessarily have a causal relationship with this treatment, or any such occurrence or worsening of a pre-existing medical condition from the first dose of investigational product through the last study visit. A serious adverse event is defined as an AE that is fatal or life threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other significant medical hazard. The relationship of each AE to the study drug was assessed by the investigator. The severity of each AE was graded using using CTCAE 3.0; For any AEs not listed in CTCAE, the Amgen Standard Severity Scoring System was used: 1: Mild- Aware of sign or symptom, but easily tolerated; 2 Moderate- Discomfort enough to cause interference with usual activity; 3: Severe- Incapacitating with inability to work or do usual activity; 4: Life-threatening; 5: Fatal.</description>
          <population>All participants who received at least one dose of romiplostim</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥ 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leading to discontinuation from study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related grade ≥ 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related grade ≥ 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related grade ≥ 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related -&gt; discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related -&gt; discontinuation from study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Antibodies or Neutralizing Antibodies to Romiplostim or to Endogenous Thrombopoietin</title>
        <description>Two validated assays were used to test for antibodies to romiplostim, the thrombopoietin-mimetic peptide component of romiplostim (TMP) and to endogenous thrombopoietin (TPO). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies.
Persistent antibodies were those positive at the last timepoint tested and transient are defined as positive post-dose but negative at the last time point tested.</description>
        <time_frame>Every 24 weeks and at the end of study visit (4 weeks or 12 weeks after study drug discontinuation).</time_frame>
        <population>All participants who received at least one dose of romiplostim.</population>
        <group_list>
          <group group_id="O1">
            <title>Romiplostim</title>
            <description>Participants received once weekly romiplostim for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Antibodies or Neutralizing Antibodies to Romiplostim or to Endogenous Thrombopoietin</title>
          <description>Two validated assays were used to test for antibodies to romiplostim, the thrombopoietin-mimetic peptide component of romiplostim (TMP) and to endogenous thrombopoietin (TPO). The first was an immunoassay to confirm the presence of antibodies. The second was a cell-based bioassay to detect neutralizing or inhibitory effects in vitro. If a sample was positive in both assays, a participant was defined as positive for neutralizing antibodies.
Persistent antibodies were those positive at the last timepoint tested and transient are defined as positive post-dose but negative at the last time point tested.</description>
          <population>All participants who received at least one dose of romiplostim.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Antibodies to romiplostim</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent antibodies to romiplostim</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient antibodies to romiplostim</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibodies to TMP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent antibodies to TMP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient antibodies to TMP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibodies to TPO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent antibodies to TPO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient antibodies to TPO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing antibodies to romiplostim</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing antibodies to TPO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug until 4 weeks after treatment discontinuation or 12 weeks after treatment discontinuation for patients who developed collagen fibrosis or a change to grade 3 reticulin; the overall median treatment duration was 154 weeks.</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 1.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Year 1 Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 2.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>Year 1 Participants received once weekly romiplostim for 3 years and had a bone marrow biopsy at Baseline and Year 3.</description>
        </group>
        <group group_id="E4">
          <title>Overall</title>
          <description>Participants received once weekly romiplostim for 3 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Diathesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Idiopathic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Conjunctival Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hyphaema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Acute Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gingival Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Portal Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Fungal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Clostridium Test Positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Plasma Cell Myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Complicated Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Sensory Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Spinal Claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Calculus Urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pulmonary Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pulmonary Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Lichenoid Keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Skin Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee Operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Tooth Extraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Peripheral Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="154" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Idiopathic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Gingival Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Mouth Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Local Swelling</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

